Pharmaceutical and biotech companies are spending years and millions of dollars developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better.

“Ensuring that the sponsor company and manufacturing partner are aligned is absolutely a key to the success of a product launch. Catalent, having touched nearly 50% of FDA approvals in the last 10 years, has the expertise to bring biologics, small molecules, vaccines, and more to market for drug sponsors,” says Jason Spacek, Vice President, Commercial Operations, North America at Catalent Biologics.